Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”

Detalles Bibliográficos
Autor principal: Mantelli, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684829/
https://www.ncbi.nlm.nih.gov/pubmed/36417164
http://dx.doi.org/10.1007/s40121-022-00727-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684829/
https://www.ncbi.nlm.nih.gov/pubmed/36417164
http://dx.doi.org/10.1007/s40121-022-00727-4

Ejemplares similares